Navidea Biopharmaceuticals Awarded New US Patent for NAV5001
November 14, 2013 at 08:36 AM EST
Navidea Biopharmaceuticals (NYSE: NAVB ) today announced that the U.S. Patent and Trademark Office (USPTO) has issued a new patent covering the formulation of the Company's radiolabeled dopamine
